兰州地区献血者人细小病毒B19分子流行病学调查  

Molecular epidemiological investigations of human parvovirus B19 among blood donors in Lanzhou

作　　者：吴康乐[1] 杨树龙[1] 冯惟萍[1] 王玮蓉 潘登[1] WU Kangle;YANG Shulong;FENG Weiping;WANG Weirong;PAN Deng(Gansu Red Cross Blood Center,Lanzhou 730046,China)

机构地区：[1]甘肃省红十字血液中心,甘肃兰州730046

出　　处：《中国输血杂志》2025年第1期68-72,共5页Chinese Journal of Blood Transfusion

基　　金：甘肃省卫生健康行业科研计划项目(GSWSKY2020-26)。

摘　　要：目的了解兰州地区献血人群中人细小病毒B19(human parvovirus B19,简称B19)的分子流行率和基因型,为监测本地献血人群的B19 DNA阳性率提供数据支持。方法运用实时荧光PCR技术随机批次筛查2022年1—9月献血者标本7644份,筛查B19 DNA阳性标本23份,采用SPSS 22.0对B19 DNA阳性献血者从性别、年龄、献血动员方式、献血次数等特征进行分析,将B19 DNA反应性标本的VP1基因片段进行测序,并运用N-J法构建进化树。结果兰州地区献血者B19 DNA阳性率为0.30%,以女性、18~30岁、个人献血、初次献血为阳性人群特征,其基因型为基因亚型1a。结论兰州地区献血者B19 DNA阳性率较低,以基因亚型1a为主。建议不定期监测献血人群B19流行率,加强监控,提升血液质量和安全水平。Objective To investigate the molecular prevalence and genotype of human parvovirus B19(B19)among blood donors in Lanzhou,and provide data support for monitoring the positive rate of B19 DNA in local blood donors.Methods A total of 7644 blood donor samples collected from January to September 2022 were randomly screened using real-time fluorescent PCR,resulting in 23 samples testing positive for B19 DNA.The characteristics of the B19 DNA reactive donors including gender,age,blood donation recruitment and promotion mode,and donation frequency were analyzed using SPSS 22.0.Additionally,the VP1 gene fragment of B19 DNA reactive samples was sequenced and an evolutionary tree was constructed by the N-J method.Results The results showed that the positive rate of B19 DNA in Lanzhou was 0.30%,and the positive population mainly consisted of female individuals aged 18-30 years old who were first-time blood donors;furthermore,genotype 1a was identified as predominant.Conclusion The positive rate of B19 DNA is low among blood donors in Lanzhou,with genotype 1a being predominant.It is recommended to periodically monitor the B19 prevalence in blood donors and enhance prevention and control measures,thus improving blood quality and safety.

关 键 词：人细小病毒B19 献血者 基因型 

分 类 号：R457.1[医药卫生—治疗学] R446[医药卫生—临床医学]